Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Poseida Therapeutics's PMUC1CALLO-1?
PMUC1CALLO-1 is a gene-modified cell therapy commercialized by Poseida Therapeutics, with a leading Phase I program in Triple-Negative Breast Cancer...